Literature DB >> 25577247

Arginase-1 is a more sensitive marker than HepPar-1 and AFP in differential diagnosis of hepatocellular carcinoma from nonhepatocellular carcinoma.

Wei Sang1, Wei Zhang, Wenli Cui, Xinxia Li, Gulinar Abulajiang, Qiaoxin Li.   

Abstract

Distinguishing hepatocellular carcinoma (HCC) from metastatic tumors is a challenging issue, especially in differential diagnosis between poorly differentiated HCC and metastasis tumors. Expression of Arg-1, HepPar-1, and α-fetoprotein (AFP) in 78 cases of HCC, 34 cases of metastatic tumors, and 228 cases of nonhepatocellular tumors of surgical specimens is measured by immunohistochemistry. Arg-1 immunoreactivity was detected in 75 of 78 (96.1 %) cases of HCC, whereas HepPar-1 and AFP immunoreactivity was detected in 63 of 78 (80.7 %) and 40 of 78 (51.3 %) cases of HCC, respectively. HepPar-1 and AFP expression was observed in three of 34 (8.8 %) cases and one of 34 (2.9 %) cases of metastatic tumors, respectively. In contrast, Arg-1 expression was absent in all 34 (0 %) cases of metastatic tumors. The sensitivity, specificity, positive predictive value, and negative predictive value of Arg-1 in distinguishing HCC from metastatic tumors and nonhepatocellular tumors are 96.1, 99.6, 98.7, and 98.8 % compared with 80.7, 92.0, 75.0, and 94.1 % for HepPar-1 and 51.3, 97.7, 87.0, and 87.1 % for AFP, respectively. Arg-1 is a more sensitive and better specific marker for HCC compared with HepPar-1 and AFP, indicating that Arg-1 can be easily applied in distinguishing HCC from metastatic tumors.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25577247     DOI: 10.1007/s13277-014-3030-6

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  26 in total

Review 1.  Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis.

Authors:  Asmaa-Ibrahim Gomaa; Shahid-A Khan; Mireille-B Toledano; Imam Waked; Simon-D Taylor-Robinson
Journal:  World J Gastroenterol       Date:  2008-07-21       Impact factor: 5.742

2.  Oncofetal protein glypican-3 in testicular germ-cell tumor.

Authors:  Satoshi Ota; Michiyo Hishinuma; Naoko Yamauchi; Akiteru Goto; Teppei Morikawa; Tetsuya Fujimura; Tadaichi Kitamura; Tatsuhiko Kodama; Hiroyuki Aburatani; Masashi Fukayama
Journal:  Virchows Arch       Date:  2006-08-04       Impact factor: 4.064

3.  Utilization of hepatocyte-specific antibody in the immunocytochemical evaluation of liver tumors.

Authors:  M I Minervini; A J Demetris; R G Lee; B I Carr; J Madariaga; M A Nalesnik
Journal:  Mod Pathol       Date:  1997-07       Impact factor: 7.842

4.  Immunoreactivity of Hep Par 1 in hepatic and extrahepatic tumors and its correlation with albumin in situ hybridization in hepatocellular carcinoma.

Authors:  Sanjay Kakar; Trudie Muir; Linda M Murphy; Ricardo V Lloyd; Lawrence J Burgart
Journal:  Am J Clin Pathol       Date:  2003-03       Impact factor: 2.493

5.  Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein.

Authors:  Peiguo G Chu; Shin Ishizawa; Emerald Wu; Lawrence M Weiss
Journal:  Am J Surg Pathol       Date:  2002-08       Impact factor: 6.394

6.  Arginase-1, HepPar-1, and Glypican-3 are the most effective panel of markers in distinguishing hepatocellular carcinoma from metastatic tumor on fine-needle aspiration specimens.

Authors:  Dana T Timek; Jianhui Shi; Haiyan Liu; Fan Lin
Journal:  Am J Clin Pathol       Date:  2012-08       Impact factor: 2.493

7.  Expression of glypican 3 in ovarian and extragonadal germ cell tumors.

Authors:  Debra L Zynger; Michael J Everton; Nikolay D Dimov; Pauline M Chou; Ximing J Yang
Journal:  Am J Clin Pathol       Date:  2008-08       Impact factor: 2.493

8.  Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

Authors:  Sean F Altekruse; Katherine A McGlynn; Marsha E Reichman
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

Review 9.  Best practices in diagnostic immunohistochemistry: hepatocellular carcinoma versus metastatic neoplasms.

Authors:  Sanjay Kakar; Allen M Gown; Zachary D Goodman; Linda D Ferrell
Journal:  Arch Pathol Lab Med       Date:  2007-11       Impact factor: 5.534

10.  Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions.

Authors:  Hanlin L Wang; Florencia Anatelli; Qihui Jim Zhai; Brian Adley; Shang-Tian Chuang; Ximing J Yang
Journal:  Arch Pathol Lab Med       Date:  2008-11       Impact factor: 5.534

View more
  8 in total

1.  Role of Glypican-3 in the growth, migration and invasion of primary hepatocytes isolated from patients with hepatocellular carcinoma.

Authors:  Mauro Montalbano; Cristiana Rastellini; Joshua T McGuire; Janika Prajapati; Ali Shirafkan; Renza Vento; Luca Cicalese
Journal:  Cell Oncol (Dordr)       Date:  2017-12-04       Impact factor: 6.730

2.  The Diagnostic Value of Arginase-1, FTCD, and MOC-31 Expression in Early Detection of Hepatocellular Carcinoma (HCC) and in Differentiation Between HCC and Metastatic Adenocarcinoma to the Liver.

Authors:  Osama H Labib; Ola A Harb; Osama H Khalil; Taha A Baiomy; Loay M Gertallah; Rham Z Ahmed
Journal:  J Gastrointest Cancer       Date:  2020-03

3.  In Silico Analysis Validates Proteomic Findings of Formalin-fixed Paraffin Embedded Cutaneous Squamous Cell Carcinoma Tissue.

Authors:  Ali Azimi; Kimberley L Kaufman; Marina Ali; Steven Kossard; Pablo Fernandez-Penas
Journal:  Cancer Genomics Proteomics       Date:  2016 11-12       Impact factor: 4.069

4.  Ductular reaction, cytokeratin 7 positivity, and gamma-glutamyl transferase in multistage hepatocarcinogenesis in rats.

Authors:  Andrea Janz Moreira; Graziella Ramos Rodrigues; Silvia Bona; Leila Xavier Sinigaglia Fratta; Giovana Regina Weber; Jaqueline Nascimento Picada; Jorge Luiz Dos Santos; Carlos Thadeu Cerski; Claudio Augusto Marroni; Norma Possa Marroni
Journal:  Protoplasma       Date:  2016-08-15       Impact factor: 3.356

5.  Efficacy of expressions of Arg-1, Hep Par-1, and CK19 in the diagnosis of the primary hepatocellular carcinoma subtypes and exclusion of the metastases.

Authors:  Ihab Shafek Atta
Journal:  Histol Histopathol       Date:  2021-07-13       Impact factor: 2.303

6.  Diagnostic Value of Arginase-1 and Glypican-3 in Differential Diagnosis of Hepatocellular Carcinoma, Cholangiocarcinoma and Metastatic Carcinoma of Liver.

Authors:  Bita Geramizadeh; Nasibe Seirfar
Journal:  Hepat Mon       Date:  2015-07-23       Impact factor: 0.660

7.  The significance of arginase-1 expression in the diagnosis of liver cancer: A protocol for a systematic review.

Authors:  Xuejiao Wang; Yifei Xu; Ruochong Wang; Ning Dai; Wei Zhang; Feng Li
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.889

8.  Large-Scale Tissue Microarray Evaluation Corroborates High Specificity of High-Level Arginase-1 Immunostaining for Hepatocellular Carcinoma.

Authors:  Maximilian Lennartz; Eva Gehrig; Sören Weidemann; Natalia Gorbokon; Anne Menz; Franziska Büscheck; Claudia Hube-Magg; Andrea Hinsch; Viktor Reiswich; Doris Höflmayer; Christoph Fraune; Frank Jacobsen; Christian Bernreuther; Patrick Lebok; Guido Sauter; Waldemar Wilczak; Stefan Steurer; Eike Burandt; Andreas H Marx; Ronald Simon; Till Krech; Till S Clauditz; Sarah Minner; David Dum; Ria Uhlig
Journal:  Diagnostics (Basel)       Date:  2021-12-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.